Two powerful congressional house Committees Demand investigating. The controversial federal approval of Biogen’s Alzheimer’s drug, Aduhelm, demanded extensive information. Documents from the Food and Drug Administration on Thursday, making it clear that the committees’ leaders troubled by unusual actions the agency took in the course of evaluating and approving the drug. “We are concerned by…
